Alkermes Plc (ALKS)vsTeva Pharma Industries Ltd ADR (TEVA)
ALKS
Alkermes Plc
$45.25
+2.10%
HEALTHCARE · Cap: $6.92B
TEVA
Teva Pharma Industries Ltd ADR
$39.97
+3.75%
HEALTHCARE · Cap: $46.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 938% more annual revenue ($17.32B vs $1.67B). TEVA leads profitability with a 4.1% profit margin vs 4.0%. TEVA appears more attractively valued with a PEG of 1.02. ALKS earns a higher WallStSmart Score of 46/100 (D+).
ALKS
Hold46
out of 100
Grade: D+
TEVA
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.9%
Fair Value
$75.72
Current Price
$45.25
$30.47 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 27.0% year-over-year
Earnings expanding 72.2% YoY
Areas to Watch
Expensive relative to growth rate
4.0% margin — thin
Premium valuation, high expectations priced in
Earnings declined 99.4%
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Revenue Growth. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth. PEG of 1.02 suggests the stock is reasonably priced for its growth.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, Profit Margin, P/E Ratio. A P/E of 108.5x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 66.6x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
ALKS profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.82 — expect wider price swings.
ALKS is growing revenue faster at 27.0% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
ALKS scores higher overall (46/100 vs 44/100) and 27.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?